112 results about "Pulmonary arterial pressure" patented technology

Methods of treating, preventing and managing pulmonary hypertension are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate (e.g., hydrate), stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, surgery and/or lung transplantation. Specific second active agents are capable of reducing pulmonary artery pressure. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive device may include a biodegradable material that biodegrades to offset flow changes caused by tissue ingrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

Devices and methods for therapy control based on electromechanical timing involve detecting electrical activation of a patient's heart, and detecting mechanical cardiac activity resulting from the electrical activation. A timing relationship is determined between the electrical activation and the mechanical activity. A therapy is controlled based on the timing relationship. The therapy may improve intraventricular dyssynchrony of the patient's heart, or treat at least one of diastolic and systolic dysfunction and/or dyssynchrony of the patient's heart, for example. Electrical activation may be detected by sensing delivery of an electrical stimulation pulse to the heart or sensing intrinsic depolarization of the patient's heart. Mechanical activity may be detected by sensing heart sounds, a change in one or more of left ventricular impedance, ventricular pressure, right ventricular pressure, left atrial pressure, right atrial pressure, systemic arterial pressure and pulmonary artery pressure.

Embodiments of the invention are related to methods and systems for using a pulmonary artery pressure signal to detect and/or monitor physiological parameters, physiological status, and aspects of disorders and diseases, amongst other things. In an embodiment, the invention includes a method of measuring a pulmonary function parameter of a patient. In an embodiment, the invention includes a method of detecting a sleeping disorder. In an embodiment, the invention includes a method of tracking sleep characteristics of a patient. Other aspects and embodiments are provided herein.

Devices, methods, and systems for determining a systolic pulmonary artery pressure index (PAPi) corresponding to pulmonary artery pressure (PAP) and/or right ventricular systolic pressure (RVSP) use lead-based electronic sensors detecting right heart valvular events. Suitable sensors include impedance sensors, accelerometers, cardiomechanical electric sensors, and sonomicrometers.

Embodiments of the invention are related to methods and systems for using a pulmonary artery pressure signal to detect and/or monitor physiological parameters, physiological status, and aspects of disorders and diseases, amongst other things. In an embodiment, the invention includes a method for detecting pulmonary symptoms of a disorder. In an embodiment, the invention includes a method for detecting a pathological change to a tissue, structure, or fluid volume in or around the lung. In an embodiment, the invention includes a method for detecting a disorder affecting airflow. Other aspects and embodiments are provided herein.

A method for diagnosing pulmonary hypertension from phase-contrast magnetic resonance (MR) images includes providing a time series of one or more magnetic resonance (MR) flow images of a patient's mediastinum during one or more cardiac cycles, segmenting the pulmonary artery within each image of the times series of images, identifying the anterior wall and pulmonary valve within the segmented pulmonary artery, analyzing blood flow during a diastolic phase of the one or more cardiac cycles to determine a relative duration of blood flow, t_streamlines, during the diastolic phase, analyzing blood flow during a latter portion of a systolic phase and a subsequent diastolic phase of the one or more cardiac cycles to detect the presence and duration t_vortex of a vortex, and diagnosing the presence of pulmonary hypertension from t_streamlines and t_vortex.

Techniques are provided for detecting pulmonary congestion based on an increase in right ventricular (RV) stroke volume over left ventricular (LV) stroke volume. In one example, the device generates an index based on accumulated differences between RV stroke volume and LV stroke volume while RV stroke volume exceeds LV stroke volume, such that the index is indicative of an ongoing imbalance between RV and LV stroke volume. The index is compared to a suitable threshold to detect a severe imbalance indicative of pulmonary edema. Additionally, techniques are described for estimating RV and LV stroke volumes based on pulmonary artery pressure, left atrial pressure, aortic pressure, LV strain or on various intracardiac or extracardiac impedance measurements.

Methods of treating, preventing and managing pulmonary hypertension are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate (e.g., hydrate), stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, surgery and/or lung transplantation. Specific second active agents are capable of reducing pulmonary artery pressure. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Systems and methods for delivering a device for regulating blood pressure between a patient's left atrium and right atrium are provided. The delivery apparatus may include a first catheter, a hub distal to the first catheter, the hub having one or more engagers disposed thereon, the one or more engagers configured to releasably engage with a first expandable end of the shunt in a contracted delivery state within a lumen of a sheath, and an second catheter extending through a center lumen of the first catheter and the hub, wherein the first catheter, the hub, and the second catheter are independently moveable relative to the sheath. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The administration of aerosolized nitric oxide donors or type V phosphodiesterase inhibitor in controlled doses to horses during high intensity exercise is described. Aerosolized nitric oxide donors (in conjunction with intravenous type V phosphodiesterase inhibitor) and type V phosphodiesterase inhibitor are beneficial to prevent exercise induced pulmonary hemorrhage by reducing transmural pulmonary artery pressure with a concomitant decrease in pulmonary capillary stress failure. The administration of aerosolized nitric oxide donors and type V phosphodiesterase inhibitors is viewed as a novel therapeutic modality in the alleviation of capillary stress failure and EIPH in performance horses.

A system comprising a multi-sensor catheter for monitoring of a cardiac hemodynamic condition, e.g. heart failure, is disclosed. The multi-sensor catheter comprises multi-lumen catheter tubing comprising first and second optical pressure sensors, and their respective optical fibers and connectors. For right heart and pulmonary artery catheterization, a flow-directed multi-sensor catheter comprises a guidewire lumen, an inflatable balloon tip, and sensor locations are configured for placement of a sensor in each of the right atrium and pulmonary artery, for measurement of central venous pressure in the right atrium and a pulmonary artery pressure. An optical fiber for oximetry may be included. The outside diameter is small enough for insertion through a vein of the arm. For monitoring of a left atrial shunt, sensors of a multi-sensor catheter are configured for measuring pressures upstream and downstream of the shunt, e.g. in the left and right atria, or left atrium and coronary sinus.

In a medical device and method to monitor pulmonary artery pressure of a patient, a first parameter related to the right ventricular straight volume of the patient's is detected, and a second parameter related to the right ventricular ejection rate of the patient's heart, or related to the workload of the patient's heart, is also determined. A pulmonary pressure index is determined by combining the first and second parameters, with variations of the pulmonary pressure index indicating variations in the pulmonary artery pressure. Pulmonary artery hypertension can be monitored with such a device and method.

Techniques are provided for use with a pulmonary artery pressure (PAP) monitor having an implantable PAP sensor. In one example, a PAP signal is sensed that is representative of beat-by-beat variations in PAP occurring during individual cardiac cycles of the patient. The PAP monitor detects peaks within the PAP signal corresponding to valvular regurgitation within the heart, then detects mitral regurgitation (MR) based on the peaks. In other examples, the PAP monitor optimizes pacing parameters based on the PAP signal and corresponding electrical cardiac signals. Examples are provided where the PAP monitor is an external system and other examples are provided where the PAP monitor is a component of an implantable cardiac rhythm management device.

Devices and methods for monitoring physiologic parameters are described herein which may utilize a non-invasive respiratory monitor to detect minor variations in expiratory airflow pressure known as cardiogenic oscillations which are generated by changes in the pulmonary blood volume that correspond with the cardiac cycle. These cardiogenic oscillations are a direct indicator of cardiac function and may be used to correlate various physiologic parameters such as stroke volume, pulmonary artery pressure, etc.

Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.

Techniques are provided for use with a pulmonary artery pressure (PAP) monitor having an implantable PAP sensor. In one example, a PAP signal is sensed that is representative of beat-by-beat variations in PAP occurring during individual cardiac cycles of the patient. The PAP monitor detects intervals within the signal corresponding to the durations of cardiac cycles, then detects cardiac rhythm irregularities based on the intervals. For example, the PAP monitor can detect and distinguish atrial fibrillation, ventricular fibrillation and ventricular tachycardia based on the stability of the intervals of the PAP signal along with other information such as ventricular rate. The PAP monitor can also detect and distinguish premature contractions based on durations of the intervals. Examples where the PAP monitor is a component of an implantable cardiac rhythm management device (CRMD) are also provided.

Systems and methods using a database of physiological information for the design, development, testing and use of therapeutics. In one aspect, the physiological information can include at least one of: hemodynamic monitoring information, pulmonary arterial pressure, cardiac output, heart rate, respiratory rate, peripheral vascular resistance, total peripheral resistance or dicrotic notch information. Optionally, the cardiovascular physiology information can include ambulatory physiological information.

The invention relates to a Chinese medicinal composition for treating broiler abdominal dropsy and a preparation method thereof. The Chinese medicinal composition is characterized by consisting of the following medicaments in part by weight: 48 to 52 parts of root of red-rooted salvia, 28 to 32 parts of szechuan lovage rhizome and 18 to 22 parts of tuckahoe. The preparation method comprises the following steps of: weighing the root of red-rooted salvia, the szechuan lovage rhizome and the tuckahoe serving as raw materials according to the weight ratio; crushing and screening to ensure that the particle diameter is between 60 and 200 meshes; and sub-packaging to obtain the finished product. The Chinese medicinal composition has the advantages that: the szechuan lovage rhizome and the root of red-rooted salvia in the prescription are common medicaments for activating blood circulation to dissipate blood stasis according to etiology and pathogenesis of the broiler abdominal dropsy; the modern pharmacological researches show that the szechuan lovage rhizome can relax lung blood vessels and reduce pulmonary artery pressure; and the root of red-rooted salvia and the szechuan lovage rhizome can also expand coronary vessels and increase blood supply of heart so as to obviously improve the function of the heart. By the method, the occurrence rate of the broiler abdominal dropsy can be greatly reduced in outdoor expansion tests under natural conditions.